REGN-COV2 is an artificial "antibody cocktail" designed to produce resistance to the SARS-CoV-2 coronavirus. It consists of a mixture of two monoclonal antibodies. The combination of antibodies is intended to prevent mutational escape. No formal human trial study has been
published to date, preliminary results were announced in a press release.
|
|
|
|
|
|
|
Positive
|
Early |
Regeneron (Preprint) |
recov. time, ↓38.0%, p=0.22 |
Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients |
| Analysis of the first 275 patients in a trial of the REGN-COV2 antibody cocktail showing reductions in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. Greatest improvements were seen with patients.. |
|
Positive
|
Early treatment study
|
| Regeneron (Preprint) |
| Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients |
| Analysis of the first 275 patients in a trial of the REGN-COV2 antibody cocktail showing reductions in viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. Greatest improvements were seen with patients that had not mounted their own effective immune response prior to treatment.The mean time-weighted-average change from baseline nasopharyngeal viral load through Day 7 in the seronegative (no measurable antiviral antibodies) group was a 0.60 log10 copies/mL greater reduction (p=0.03) in patients treated with high dose, and a 0.51 log10 copies/mL greater reduction (p=0.06) in patients treated with low dose, compared to placebo. In the overall population, there was a 0.51 log10 copies/mL greater reduction (p=0.0049) in patients treated with high dose, and a 0.23 log10 copies/mL greater reduction (p=0.20) in patients treated with low dose, compared to placebo.Among seronegative patients, median time to symptom alleviation (defined as symptoms becoming mild or absent) was 13 days in placebo, 8 days in high dose (p=0.22), and 6 days in low dose (p=0.09).Adverse reactions were similar with treatment and placebo. There were no deaths.
recovery time, ↓38.0%, p=0.22, high dose median time to recovery
recovery time, ↓54.0%, p=0.09, low dose median time to recovery
|
|
Source
Study Page
Submit Corrections or Comments
|
|
In Vitro
|
In Vitro |
Baum et al., Science, 21 Aug 2020, 369:6506, 1014-1018, doi:10.1126/science.abd0831 (Peer Reviewed) (In Vitro) |
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies |
| In Vitro study showing that, under pressure from individual antibodies, mutant viruses were rapidly selected that evaded the blocking function of all individual antibodies tested, including antibodies that potently bind to highly-conserve.. |
|
In Vitro
|
In Vitro
|
| Baum et al., Science, 21 Aug 2020, 369:6506, 1014-1018, doi:10.1126/science.abd0831 (Peer Reviewed) (In Vitro) |
| Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies |
In Vitro study showing that, under pressure from individual antibodies, mutant viruses were rapidly selected that evaded the blocking function of all individual antibodies tested, including antibodies that potently bind to highly-conserved regions on the spike protein. However, escape mutants could not be efficiently generated following exposure to the REGN-COV2 cocktail since it utilizes two antibodies that can simultaneously bind to distinct regions of the RBD.
![]()
|
|
Source
Study Page
Submit Corrections or Comments
|
|
Animal
|
N/A |
Hansen et al., Science, 21 Aug 2020, 369:6506, 1010-1014, doi:10.1126/science.abd0827 (Peer Reviewed) |
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail |
| Study using humanized mice and blood samples from recovered COVID-19 patients to generate antibodies targeting multiple different regions of the critical receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The spike protein on .. |
|
Animal
|
N/A
|
| Hansen et al., Science, 21 Aug 2020, 369:6506, 1010-1014, doi:10.1126/science.abd0827 (Peer Reviewed) |
| Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail |
Study using humanized mice and blood samples from recovered COVID-19 patients to generate antibodies targeting multiple different regions of the critical receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The spike protein on the virus cell surface binds to the host cell and is required for infectivity. By blocking its interaction with the host cell, antibodies are able to neutralize the virus and block infection. Authors selected pairs of highly potent individual antibodies that simultaneously and non-competitively bind to the RBD. The multi-antibody approach is used to decrease the potential for the virus to escape.
![]()
|
|
Source
Study Page
Submit Corrections or Comments
|
